Evaluation of alum-based adjuvant on the immunogenicity of salmonella enterica serovar typhi conjugates vaccines
- PMID: 29359991
- PMCID: PMC6037457
- DOI: 10.1080/21645515.2018.1431599
Evaluation of alum-based adjuvant on the immunogenicity of salmonella enterica serovar typhi conjugates vaccines
Abstract
The function of adjuvant in maintaining the long-term immune response to Typhoid conjugate vaccine (TCV) was evaluated in. Two TCV products, Vi-DT and Vi-TT, were formulated in either aluminum phosphate (AlPO4) or aluminum hydroxide (AlOH) as adjuvants and TCV formulated in phosphate buffer saline were used as controls. In each case, a group of Balb/c mice was injected intramuscularly with two doses of the formulated vaccine at two-week intervals. The anti-Vi IgG responses were monitored by Enzyme-Linked Immunosorbent Assay and the levels of CD4+ T-cells expressing cytokine were characterized using intracellular cytokine staining. All mice immunized by TCV formulated in adjuvant elicited anti-Vi response to a higher level than the group receiving TCV formulated in PBS. The extent of adsorption of TCV in AlOH was greater than that in AlPO4, and this finding correlated well with the observation that the mice immunized with two doses of Vi-DT(AlOH) elicited anti-Vi IgG to a level higher than that seen with Vi-DT(AlPO4). The mice primed with Vi-TT(AlOH) produced lower anti-Vi IgG (25.901 GM) compared to those receiving Vi-TT(AlPO4) (49.219 GM). However, after the second injection, the former raised the antibody level significantly to 137.008 GM while the latter provided a value of only 104.966 GM. The groups of mice vaccinated by TCV formulated in AlOH expressed IL4 at higher levels than the other groups, which correlated positively with the high Anti-Vi IgG in these animals. In conclusion, AlOH could be recommended as an effective adjuvant for TCV to provide a long-term immune response.
Keywords: Typhoid conjugate vaccine; Vi; adjuvant; anti-Vi IgG; cytokine; diphteria toxoid; tetanus toxoid.
Similar articles
-
A TLR4 ligand-based adjuvant for promoting the immunogenicity of typhoid subunit vaccines.Front Immunol. 2024 May 10;15:1383476. doi: 10.3389/fimmu.2024.1383476. eCollection 2024. Front Immunol. 2024. PMID: 38799439 Free PMC article.
-
Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study.Clin Infect Dis. 2015 Aug 1;61(3):393-402. doi: 10.1093/cid/civ295. Epub 2015 Apr 13. Clin Infect Dis. 2015. PMID: 25870324 Clinical Trial.
-
Comparison of anti-Vi IgG responses between two clinical studies of typhoid Vi conjugate vaccines (Vi-DT vs Vi-TT).PLoS Negl Trop Dis. 2020 Mar 23;14(3):e0008171. doi: 10.1371/journal.pntd.0008171. eCollection 2020 Mar. PLoS Negl Trop Dis. 2020. PMID: 32203521 Free PMC article. Clinical Trial.
-
Host-Salmonella interaction: human trials.Microbes Infect. 2001 Nov-Dec;3(14-15):1271-9. doi: 10.1016/s1286-4579(01)01487-3. Microbes Infect. 2001. PMID: 11755415 Review.
-
Development of Vi conjugate - a new generation of typhoid vaccine.Expert Rev Vaccines. 2013 Nov;12(11):1273-86. doi: 10.1586/14760584.2013.845529. Expert Rev Vaccines. 2013. PMID: 24156285 Review.
Cited by
-
Intranasal immunization of mice with chimera of Salmonella Typhi protein elicits protective intestinal immunity.NPJ Vaccines. 2024 Feb 6;9(1):24. doi: 10.1038/s41541-024-00812-4. NPJ Vaccines. 2024. PMID: 38321067 Free PMC article.
-
Pathogenic signature of invasive non-typhoidal Salmonella in Africa: implications for vaccine development.Hum Vaccin Immunother. 2020 Sep 1;16(9):2056-2071. doi: 10.1080/21645515.2020.1785791. Epub 2020 Jul 21. Hum Vaccin Immunother. 2020. PMID: 32692622 Free PMC article. Review.
References
-
- Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baiqing D, Bhattacharya SK, Agtini MD, Bhutta ZA, Canh DG, Ali M, Shin S, et al. . A study of typhoid fever in five Asian countries: Disease burden and implications for controls. Bull World Health Organ. 2008;86:260–8. doi:10.2471/BLT.06.039818. PMID:18438514 - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials